AstraZeneca, atugen Enter Validation, Drug-Discovery Alliance | GenomeWeb

NEW YORK, Oct. 16 – German biotech company atugen and AstraZeneca plan to use atugen’s GeneBloc technology to enhance target validation and drug development in an undisclosed number of “major disease areas” of interest to AstraZeneca.

Terms of the deal call for Berlin-based atugen to retain all rights to specific GeneBlocs it develops for the drugs giant and will have an option to license certain intellectual property generated in the collaboration, according to a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.